| Sudden progression from impaired glucose tolerance to type 2 diabetes after discontinuation of administration of anti-tumor necrosis factor-alpha antibody infliximab. | |
| | |
MedLine Citation:
|
PMID: 20943070 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
We present the case of a 45-year-old man with psoriasis and psoriatic arthritis and concomitant impaired fasting glucose (IFG) and impaired glucose tolerance (IGT). In this patient, refractory to DMARD's, infliximab was started to control the arthritis. After achieving clinical remission of the disease, infliximab was discontinued and a 75 g- oral glucose tolerance test (OGTT) was performed. After the test, we observed a conversion from IFG/IGT glucose tolerance status to type 2 diabetes. No diet, lifestyle or therapy modifications were made during the observation period. Autoimmune diabetes was ruled out by serum antibodies determination and body weight remained constant, sustaining a protective role in infliximab in the worsening of glucose tolerance. |
| | |
Authors:
|
F Ursini; E Succurro; A Grembiale; S Rudi; R D Grembiale; F Arturi |
Publication Detail:
|
Type: Case Reports; Letter |
Journal Detail:
|
Title: International journal of immunopathology and pharmacology Volume: 23 ISSN: 0394-6320 ISO Abbreviation: Int J Immunopathol Pharmacol Publication Date: 2010 Jul-Sep |
Date Detail:
|
Created Date: 2010-10-14 Completed Date: 2010-12-16 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8911335 Medline TA: Int J Immunopathol Pharmacol Country: Italy |
Other Details:
|
Languages: eng Pagination: 961-3 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibodies, Monoclonal
/
therapeutic use* Antirheumatic Agents / therapeutic use* Arthritis, Psoriatic / complications, drug therapy Diabetes Mellitus, Type 2 / pathology* Disease Progression Glucose Intolerance / pathology* Glucose Tolerance Test Humans Hypertension / complications Insulin Resistance Male Middle Aged Tumor Necrosis Factor-alpha / immunology |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Antirheumatic Agents; 0/Tumor Necrosis Factor-alpha; 0/infliximab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: JC Viral reactivation in a pediatric patient with Crohn's disease.
Next Document: Etanercept therapy in patients with psoriasis and concomitant HCV infection.